Of those 161 patients, 16 (10%) experienced recurrent acute pancreatitis after GLP-1 receptor agonist therapy (mean duration 10.8 7.2 months): 6 (38%) were caused by the GLP-1 receptor agonist (as clinically determined by the treating medical team), three (18%) were due to hypertriglyceridemia, two (12%) due to alcohol use, one (6%) due to another oral hypoglycemic agent, one (6%) due to ampulla stenosis, and three (19%) were idiopathic
Hence, they ensure to provide a personalized approach to weight loss, selecting the most suitable GLP-1 injection based on individual tolerance, treatment goals, lifestyle, and potential side effects
If you notice significant variation in appetite suppression or GI side effects week to week, your injection site rotation might be the variable
The drug retatrutide goes one step beyond
That works out to 28.7% of their body weight
Is Tranont a pyramid scheme